LOXO - Loxo Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
234.66
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close234.66
Open234.70
Bid0.00 x 1200
Ask0.00 x 1400
Day's Range234.66 - 234.87
52 Week Range108.75 - 234.93
Volume400
Avg. Volume1,306,655
Market Cap7.217B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est227.00
Trade prices are not sourced from all markets
  • Steven Cohen Takes Stake in Aptevo Therapeutics
    GuruFocus.com5 days ago

    Steven Cohen Takes Stake in Aptevo Therapeutics

    Guru adds biotech company to health care holdings

  • Moody's27 days ago

    Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook

    Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes issuance of Eli Lilly and Company ("Lilly"). There is no impact on Lilly's existing ratings including the A2 senior unsecured rating and the Prime-1 commercial paper rating. Proceeds of the offering are for reduction of commercial paper borrowings following Lilly's acquisition of Loxo Oncology, Inc. and for general corporate purposes.

  • GlobeNewswire28 days ago

    Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Moody'slast month

    Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Eli Lilly and Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Reuterslast month

    Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

    German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology. Bayer said on Friday it exercised a right to gain exclusive licensing rights for the global development and commercialization of Vitrakvi, also known as larotrectinib, under a clause in the initial collaboration deal with Loxo Oncology that provided for Loxo becoming a takeover target.

  • Lilly Completes Acquisition of Loxo Oncology
    PR Newswirelast month

    Lilly Completes Acquisition of Loxo Oncology

    INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a pipeline of highly selective potential medicines for patients with genomically defined cancers. Lilly's tender offer for all outstanding shares of common stock of Loxo Oncology, at a price of $235.00 per share in cash, expired as scheduled at one minute past 11:59 p.m., Eastern time, on Thursday, February 14, 2019.

  • 5 Tiny Biotech Stocks With Superb Growth Potential
    Zackslast month

    5 Tiny Biotech Stocks With Superb Growth Potential

    A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

  • Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?
    Market Realistlast month

    Pfizer or Eli Lilly: Who Will Report Better Revenue Growth?

    How Pfizer and Eli Lilly Stack Up in February(Continued from Prior Part)Revenue guidance for fiscal 2019 In its fourth-quarter earnings conference call, Pfizer (PFE) has guided for revenues of $52 billion to $54 billion for fiscal 2019 driven by the

  • Markitlast month

    See what the IHS Markit Score report has to say about Loxo Oncology Inc.

    Loxo Oncology Inc NASDAQ NMS:LOXOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for LOXO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LOXO. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LOXO totaled $2.61 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure
    Motley Foollast month

    5 Reasons Eli Lilly Investors Look Can Look Past Lartruvo's Failure

    A gleaming fourth-quarter earnings report made it a lot easier to forget about a high-profile clinical trial failure.

  • TheStreet.comlast month

    Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

    Eli Lilly said earnings for the three months ending in December came in at $1.33 per share, up 16.6% from the same period last year but just shy of the consensus forecast of $1.34. Group revenues, Eli Lilly said, were $6.438 billion, up nearly 4% from last year and ahead of the $6.28 billion forecast. Looking into 2019, however, Eli Lilly said full year earnings would be in the range of $5.55 to $5.65 per share on a non-GAAP basis, down from its previous forecast of between $5.90 and $6.10, thanks to the Loxo purchase and a negative phase 3 confirmatory trial for its Lartruvo treatment for rare soft tissue cancers.

  • Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript
    Motley Foollast month

    Eli Lilly & Co (LLY) Q4 2019 Earnings Conference Call Transcript

    LLY earnings call for the period ending December 31, 2018.

  • Reuterslast month

    Eli Lilly cuts 2019 forecast on trial failure, Loxo deal

    Indianapolis-based Lilly is betting on new drugs and pushing deeper into cancer drug development as long-term top-sellers such as diabetes drug Humalog and erectile dysfunction treatment Cialis lose market share to cheaper rivals. In January, the company said it would buy Loxo Oncology Inc for $8 billion, marking its foray into precision medicines for cancer that target rare genetic mutations.. Lilly has said it is suspending promotion of the drug and analysts expect a significant drop in sales as it will no longer be prescribed to new patients the United States.

  • Reuterslast month

    Eli Lilly backs U.S. proposal on drug rebates to lower costs

    Eli Lilly and Co on Wednesday embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen, saying it could lower the cost of insulin and other prescription drugs for patients. Lilly, along with other major insulin makers, Sanofi SA and Novo Nordisk, has been under mounting pressure from patients and politicians over the rising cost of the life-sustaining diabetes treatment. "While it's still a proposal, we see this as ... a win for patients, lowering their out-of-pocket costs at the pharmacy counter with the greatest benefit realized by patients taking more highly-rebated products such as insulin," Chief Executive David Ricks said on a call with analysts.

  • Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
    Zackslast month

    Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

    Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

  • Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript
    Motley Foollast month

    Array Biopharma Inc (ARRY) Q2 2019 Earnings Conference Call Transcript

    ARRY earnings call for the period ending December 31, 2018.

  • 5 of the Best Biotech Stocks to Buy Now
    InvestorPlacelast month

    5 of the Best Biotech Stocks to Buy Now

    It's debatable whether the stock market, as a whole, had a bear market or just a stiff correction to end 2018. There is, however, no such question about biotech stocks. The sector got clobbered last fall. The SPDR S&P Biotech ETF (NYSEARCA:XBI) dropped 35% from its September peak. It was a bear market, no doubt about it. However, pharma and biotech stocks have gotten off to a better start in 2019. Deal-making brought the sector back to life. For starters, Bristol-Meyers Squibb (NYSE:BMY) made one of the biggest deals in pharma history with its purchase of Celgene (NASDAQ:CELG). Shortly after that, Eli Lilly (NYSE:LLY) made a huge deal of its own, taking out oncology player Loxo (NASDAQ:LOXO). These big moves have investors focused again on the biotech sector. * 10 F-Rated Stocks That Could Break Your Portfolio With that in mind, here are five more biotech stocks to buy that could be winners in 2019. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock ### Gilead Sciences (GILD) Eli Lilly's deal to buy Celgene reignited the animal spirits in the biotech industry. Everyone is curious what big deal will happen next. For long-suffering biotech major Gilead Sciences (NASDAQ:GILD), it gets its turn in the spotlight now that Celgene is out of the picture. Gilead has looked cheap for a while now with its price-to-earnings ratio often below 10 in recent years. Its P/E ratio is still around 10 now. Unlike in the past, however, Gilead's Hep C franchise has just about stabilized in terms of revenues, and as such, earnings are set to rebound as well. Analysts see earnings-per-share rising from $5.40 last year to more than $6 this year and up to something in the $9 range in the year 2021. It's unlikely GILD stock will still sell under $70 once it is earning $9/share annually with EPS continuing to rise. On top of that, Gilead is very friendly to its shareholders. It has been buying back loads of its own stock in addition to its generous 3.3% dividend yield. Source: Shutterstock ### Novo Nordisk (NVO) Investors usually don't think of biotech stocks as either conservative or as good sources of dividend income. And, usually, they aren't -- we'll get to a couple more volatile high-risk, high-reward biotech names here in a minute. But for now, let's talk about Novo Nordisk (NYSE:NVO), which is the clear leader in diabetes treatment worldwide. It, like Gilead, is highly profitable and pays a strong 2.6% dividend. Novo is one of those so-called inevitable investments, in that demographics make it a very likely winner in the coming years. The rate of diabetes cases continues to explode throughout the world. Make no mistake about it: The diabetes epidemic isn't just a U.S. problem. Increasingly, even in emerging markets such as India and Mexico, diabetes-related health care costs are soaring. * 10 Cold Weather Stocks to Heat Up Your Returns Novo, which controls roughly 25% of the global market in that indication, is the logical winner from this epidemic. NVO stock plunged from its highs a couple years back on insulin pricing concerns. The stock has recovered from its worst levels but is still well short of all-time highs and sells for just 18x earnings. That's a pretty great valuation for a company whose product portfolio and addressable market continues to show serious expansion. While Novo is a very large company on its own, with a $90 billion market cap, the Celgene deal showed us that these sorts of bigger independent biotech firms can potentially be in play as well. Source: Shutterstock ### Puma Biotechnology (PBYI) Usually, biotech stocks crater after their drug fails to win Food and Drug Administration approval. Sometimes, however, a drug gets FDA approval and then the stock still plummets anyway. Meet Puma Biotechnology (NASDAQ:PBYI). Puma is a victim of the biotech disease known as the slow new drug launch. Puma started earning commercial revenues off its Nerlynx breast cancer adjutant in 2017. PBYI stock soared to as high as $120 as excitement around the drug launch mounted. Unfortunately, sales didn't pick up as quickly as expected. From Q3 2017 through Q3 2018, Nerlynx sales grew about $15 million per quarter compared to the prior quarter. That is solid growth, though not exponential. However, Q4 showed just a $1.8 million uptick in revenue, falling far below trend. The near absence of revenue growth combined with other concerns such as potential competition has sent investors into a state of panic. PBYI stock has plunged from as high as $83 just last spring to as low as $17 this past November. It's worth taking another look at PBYI stock now, however. At the end of the day, this is just a $1 billion market cap company doing nearly $250 million a year in revenues with a promising new cancer drug that has tests underway for other conditions beyond its initial breast cancer label. On top of that, Puma should be able to start launching its product in other markets, such as Europe, in addition to its domestic sales. Finally, if the price stays this low, Puma Biotechnology looks like a possible buyout target. Source: Shutterstock ### Aimmune Therapeutics (AIMT) Aimmune Therapeutics (NASDAQ:AIMT) offers investors an interesting catalyst trade. The company recently posted excellent results from its Phase III trial for its treatment to aid with peanut allergies. It is widely expected that Aimmune will commercially launch its product in 2019. In fact, the company already secured a $170 million loan package from KKR (NYSE:KKR) to get its peanut allergy medication commercially launched. That funding will also help fund trials of the therapy for egg allergies. Unfortunately, due to the recent government shutdown, the FDA delayed various paperwork, including Aimmune's marketing approval. With the government open again, that should come through soon, however, allowing AIMT stockholders to start focusing on the upside again. * The 7 Best Penny Stocks to Buy Ultimately, once the therapy is up and running, it should be a commercial success. The company estimates that there are 1.7 million children in the U.S. with peanut allergies, not to mention the global market. On top of that, the company is running tests for other food allergies such as eggs. At a market cap of just $1.3 billion, there's still upside for Aimmune as its product starts generating meaningful revenues. Source: Shutterstock ### Viking Therapeutics (VKTX) Finally, we have arguably the most controversial pick of the bunch, Viking Therapuetics (NASDAQ:VKTX). Make no mistake, this is among the riskier of the biotech names, and could have substantial downside if the bears are right. On the other hand, the stock could easily double or triple if events go well. What's the buzz around Viking? Last spring, VKTX stock spiked from $5 to $10 following positive clinical results from competitor Madrigal Pharmaceuticals (NASDAQ:MDGL). Madrigal and Viking's drug candidates for non-alcoholic liver disease use the same mechanism of action, thus suggesting that Viking's drug would be effective as well. Later that fall, Viking stock doubled again, hitting $20 following positive results of its own. Since then, VKTX stock has given back nearly all its gains, falling back to just $9. That is in large part due to a recent short report from Citron Research. Citron went after Ligand Pharmaceuticals (NASDAQ:LGND), causing a 22% decline in Ligand's share price. Ligand is a major backer of Viking, and Citron took some shots at Viking's prospects as well. Perhaps as a result, short sellers have pounded Viking, putting its short interest up to 37%. That could be a risky bet though, as Viking has a promising Phase 2 drug and $300 million (half the market cap) in net cash to keep doing research. At the time of this writing, Ian Bezek owned GILD and NVO stock. You can reach him on Twitter at @irbezek. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 S&P 500 Stocks to Buy That Tore Up Earnings * 10 Cold Weather Stocks to Heat Up Your Returns * The 7 Best Penny Stocks to Buy Compare Brokers The post 5 of the Best Biotech Stocks to Buy Now appeared first on InvestorPlace.

  • Here's Why Array BioPharma Jumped 31% in January
    Motley Foollast month

    Here's Why Array BioPharma Jumped 31% in January

    Investors had more than one reason to feel good about Array BioPharma last month.

  • Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
    PR Newswire2 months ago

    Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction

    INDIANAPOLIS and STAMFORD, Conn., Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) ("Lilly") and Loxo Oncology, Inc. (LOXO) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with Lilly's previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash (the "Offer Price"), or approximately $8.0 billion. Lilly's wholly-owned subsidiary, Bowfin Acquisition Corporation, commenced the tender offer on January 17, 2019 and the tender offer is scheduled to expire one minute after 11:59 P.M., Eastern time, on February 14, 2019. The transaction is not subject to any financing condition and is expected to close by the end of the first quarter of 2019, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Loxo Oncology's common stock.

  • Is the Options Market Predicting a Spike in Loxo Oncology (LOXO) Stock?
    Zacks2 months ago

    Is the Options Market Predicting a Spike in Loxo Oncology (LOXO) Stock?

    Investors need to pay close attention to Loxo Oncology (LOXO) stock based on the movements in the options market lately.

  • 5 Best Biotech Bets Likely to Outperform Estimates in Q4
    Zacks2 months ago

    5 Best Biotech Bets Likely to Outperform Estimates in Q4

    Let us take a look at five promising biotech stocks for the fourth quarter of 2018.